Supporters
Partners
Melanoma (Skin Cancer)
Melanoma is a form of skin cancer that starts in the pigment-producing skin cells called melanocytes. These cells become abnormal, grow uncontrollably and aggressively invade surrounding tissues. Although melanoma is less common than other types of skin cancer, it is the by far the most serious. Damage to the genetic material (DNA) of melanocytes from sun exposure and UV light radiation is a major cause of melanoma. The National Cancer Institute estimated in 2008 that there were 62,480 new cases.
| Company | Product | Phase | |
| Novartis AG | Proleukin (aldesleukin) | M | Melanoma |
| North American Scientific Inc | Prospera | M | Melanoma |
| Valeant Pharmaceuticals International | Efudix | M | Skin Cancer |
| Abraxis BioScience Inc | Abraxane | III | Melanoma |
| Vical Inc | Allovectin-7 | III | Melanoma |
| SciClone Pharmaceuticals Inc | Zadaxin | III | Melanoma |
| Genentech, Inc. | Tarceva with Radiation Therapy | III | Melanoma |
| Genentech, Inc. | Abraxane with Bevacizumab (First Line Therapy) | II | Melanoma |
| Abraxis BioScience, Inc. | Abraxane with Bevacizumab (First Line Therapy) | II | Melanoma |
| Abraxis BioScience, Inc. | Abraxane with Carboplatin | II | Melanoma |
| Polaris Group | ADI PEG 20 | II | Melanoma |
| Attenuon LLC | ATN-224 with temozolomide | II | Melanoma |
| Genentech Inc | Avastin | II | Melanoma |
| Genentech, Inc. | Avastin with Carboplatin and Paclitaxel (First Line Therapy) | II | Melanoma |
| Amgen Inc | CR011-vcMMAE | II | Melanoma |
| Cytokinetics Inc | Ispinesib | II | Melanoma |
| Jennerex Biotherapeutics Inc | JX594 | II | Melanoma |
| PDL BioPharma Inc | M200 with Dacarbazine | II | Melanoma |
| Hana Biosciences Inc | Marqibo | II | Melanoma |
| MannKind Corp | MKC1106-MT | II | Melanoma |
| Genentech, Inc. | RAD001 with Avastin | II | Melanoma |
| Cytokinetics Inc | SB715992 (First Line Therapy) | II | Melanoma |
| Genentech, Inc. | GDC0449 | II | Skin Cancer |
| Genentech, Inc. | Tarceva | II | Skin Cancer |
Multiple Myeloma
Multiple myeloma is a malignancy of the plasma cells, a type of white blood cell. Myeloma begins when a plasma cell becomes abnormal. Myeloma cells collect in the bone marrow and may crowd out normal blood cells. Myeloma cells also collect in the solid part of the bone. The disease is called "multiple myeloma" because it affects many bones. The National Cancer Institute estimated 19,920 new cases in 2008.
| Company | Product | Phase | |
| Attenuon LLC | ATN-224 with bortezomib | II | Multiple Myeloma |
| Amgen Inc | Denosumab | II | Multiple Myeloma |
| Johnson & Johnson | Doxil (doxorubicin hydrochloride) | II | Multiple Myeloma |
| Amgen Inc | AMG162 | II | Multiple Myeloma |
| Genentech, Inc. | Avastin with Bortezomib | II | Multiple Myeloma |
| Cougar Biotechnology, Inc. | CB3304 | II | Multiple Myeloma |
| Facet Biotech Corporation | HuLuc63 with Velcade | II | Multiple Myeloma |
| Proteolix Inc | PR171 | II | Multiple Myeloma |